We’re on the brink of a breakthrough. Our study is one step away from introducing a FDA-approved adult migraine treatment to children. Help us cross the finish line.

Migraines, debilitating and persistent, affect around 15% of adults. However, they don’t spare the young. Children, particularly those below 15 years, experience migraines that could be either bilateral or unilateral and non-throbbing. Symptoms include a pallid, sickly appearance, dizziness, blurred vision, fever, nausea, and vomiting. These young migraineurs, from as early as 7 years, may also avoid light (photophobia), noise (phonophobia), strong odors, and movement.

Research Works invites children and adolescents to join us in an exciting, compensated investigational trial based in New Orleans, Louisiana. We’re studying the effects of rimegepant, an FDA-approved adult migraine treatment.

Our clinical trial aims to test this adult-approved medication’s efficacy and safety in treating acute migraines in children and teens compared to a placebo. We’ll be involving 1,440 participants in total – approximately 1,200 adolescents and 240 children under 12. We’re specifically examining rimegepant’s safety in acute migraine treatment among the pediatric population.

Study-related care comes at no cost to you or your health insurance. To thank you for your invaluable contribution, we offer compensation for your time and travel. Qualifying candidates may receive up to $1800 during this study.
Eligibility Criteria:
  • Between ages 12 and 17
  • Experiencing at least 6, but no more than 14 migraines per month
  • Experienced migraines for at least 6 months
  • Have a medical diagnosis of pediatric migraines

Further inclusion/exclusions may apply

Join Our Study

Embark on a journey full of opportunity and progress.

  • Experience elevated healthcare
  • Sneak peek into new, developing medicines
  • No-cost medical labs and care related to the study
  • Compensation for your time and travel

Please fill out the information below and we will contact you within 24hrs.

Your information is secure and private. We will not share your information with any third party without your authorized consent.